Dual pathway inhibition as compared to acetylsalicylic acid monotherapy in relation to endothelial function in peripheral artery disease, a phase IV clinical trial

OBJECTIVE: Dual pathway inhibition (DPI) by combining acetylsalicylic acid (ASA) with low-dose rivaroxaban has been shown to reduce cardiovascular events in patients with peripheral arterial disease (PAD) when compared to ASA monotherapy. A potential explanation is that inhibition of factor Xa impro...

Descripción completa

Detalles Bibliográficos
Autores principales: Willems, Loes H., Thijssen, Dick H. J., Groh, Laszlo A., Kooijman, Nina I., Ten Cate, Hugo, Spronk, Henri M. H., Donders, A. Rogier T., van der Vijver-Coppen, Rozemarijn J., van Hoek, Frank, Nagy, Magdolna, Reijnen, Michel M. P. J., Warlé, Michiel C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583941/
https://www.ncbi.nlm.nih.gov/pubmed/36277757
http://dx.doi.org/10.3389/fcvm.2022.979819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583941/
https://www.ncbi.nlm.nih.gov/pubmed/36277757
http://dx.doi.org/10.3389/fcvm.2022.979819

Ejemplares similares